by Madaline Spencer | Oct 1, 2026
The US Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who...
by Madaline Spencer | Sep 30, 2026
The US Food and Drug Administration (FDA) has approved Emcitate (tiratricol) for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency. MCT8 deficiency is a rare disorder of brain development that causes moderate...
by Madaline Spencer | Sep 30, 2026
A study published in The Lancet evaluated the safety and efficacy of ralinepag in patients with pulmonary arterial hypertension (PAH). PAH is a rare condition affecting the heart and lungs, characterized by abnormally high blood pressure (hypertension) in the...
by Madaline Spencer | Sep 30, 2026
The US Food and Drug Administration (FDA) has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in patients ages 12 years and older with fibrodysplasia ossificans progressiva (FOP). FOP is a disorder in which...
by Madaline Spencer | Sep 29, 2026
The US Food and Drug Administration (FDA) has approved Lyrfigtu (lirafugratinib) for the treatment of cholangiocarcinoma with FGFR2 fusion or other rearrangement. Cholangiocarcinoma is a rare, aggressive cancer that forms in the bile duct. Patients with...
